Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 2, p. 99, doi. 10.1007/s11523-007-0044-7
- By:
- Publication type:
- Article
Works matching IS 17762596 AND DT 2007 AND VI 2 AND IP 2
Results: 8
1
2
Targeted therapies in head and neck cancer.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 2, p. 73, doi. 10.1007/s11523-007-0048-3
- By:
- Publication type:
- Article
3
Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 2, p. 63, doi. 10.1007/s11523-007-0042-9
- By:
- Publication type:
- Article
4
Targeted therapy for small cell lung cancer.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 2, p. 89, doi. 10.1007/s11523-007-0045-6
- By:
- Publication type:
- Article
5
Highlights from the pharmacology and molecular mechanisms group annual meeting.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 2, p. 121, doi. 10.1007/s11523-007-0046-5
- Publication type:
- Article
6
Lapatinib: a novel dual tyrosine kinase inhibitor.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 2, p. 107, doi. 10.1007/s11523-007-0047-4
- By:
- Publication type:
- Article
7
The value of innovation: the economics of targeted drugs for cancer.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 2, p. 113, doi. 10.1007/s11523-007-0043-8
- By:
- Publication type:
- Article
8
Have we made progress with biological agents in metastatic colorectal cancer?
- Published in:
- 2007
- By:
- Publication type:
- Editorial